Latest Conference Articles

COA's Nicolas Ferreyros discusses next steps for PBM reform, funding for supportive cancer services, and a hopeful outlook for community oncology.

AI, patient voice in pathways, and caregiver support are shaping community oncology, AON leaders said at Patient-Centered Oncology Care.

Cleveland Clinic's Beth Faiman, PhD, MSN, discusses advanced practitioners' reimbursement and how outpatient trispecific antibodies could increase access.

Tennessee Oncology’s Johnetta Blakely, MD, MS, explains why physicians must review high-stakes AI-assisted orders and how patients view AI in oncology.

OneOncology's Edward "Ted" Arrowsmith, MD, MPH, explains why cost stays out of its pathway process and how point-of-care ordering puts pathways to work.

Tennessee Oncology's Wade Iams, MD, MSCI, discusses insured patients' out-of-pocket costs, platinum shortages, and access to CAR T and BiTE therapies.

Nicolas Ferreyros, of COA, warns IRA drug price negotiation threatens community oncology payments and urges Part B, 340B, and insurer reforms.

Rosacea is likely missed, not rare, in skin of color, as low suspicion and hard-to-see redness delay diagnosis, said Hilary Baldwin, MD.

Hidradenitis suppurativa diagnosis often takes 7 to 10 years, and patients with skin of color often present with tunnels and scarring already in place.

Alyssa Schatz, DrPH, MSW, of NCCN, explains how insurance shifts and drug shortages threaten access to cancer care.

Those using e-cigarettes were more likely to develop cataracts, and those receiving cataract surgery less likely to develop depression and anxiety.

The conference session featured updates on several clinical trials, including the BRUNELLO trial, for treatment of diabetic macular edema (DME).

OneOncology's Larry Bilbrey discusses why unstructured data limits artificial intelligence and how practices can weigh AI purchases by their payoff.

AI tools are streamlining retina practice, but adoption depends on fitting them into real-world workflows.

Cataract surgery improved vision across all AMD stages, but patients with advanced dry AMD lost their gains by about 30 months.

Panelists engaged in a debate regarding using complement inhibitors in geographic atrophy, gauging public sentiment with a deciding vote.

New 12-month phase 1/2 data show the BIM-IOL System lowered IOP and kept most patients drop-free after cataract surgery.

In the pivotal BRUNELLO trial, both doses of remigromig, a Wnt pathway agonist, were noninferior to ranibizumab for diabetic macular edema at 1 year.

A session at AAO 2026 highlighted how big data and minimally invasive glaucoma surgery (MIGS) could be utilized to help patients receive peak care.

Access to emergency eye care remains a public health challenge, with gaps that affect patients and communities across the country.

The opening session of AAO 2026 featured a keynote speech discussing how artificial intelligence (AI) will play a part in health care.

Cost, staffing, unbiased training data, and strong referral partnerships will decide whether AI eye screening reaches patients at highest risk of vision loss.

Incidence of diabetic macular edema and the need for glaucoma surgery were reduced after treatment with glucagon-like peptide-1 receptor agonists.

The director of the National Eye Institute discusses recent advances, AI, and evolving standards of care in ophthalmology.

Two inSPire2026 posters detail how health system specialty pharmacy teams support patients with ATTR-CM.

COA's Nicolas Ferreyros discusses real-world survival data for community oncology, health system consolidation, and barriers to CAR T-cell access.

The conference, held in New Orleans, Louisiana, by the American Academy of Ophthalmology, will offer 3 full days of content spanning from glaucoma to dry eye.

Cathy Eng, MD, discusses a BREAKWATER post hoc analysis showing poorer survival in early-onset BRAF V600E colorectal cancer.